Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient's tumor - - Patent applies to any modality, including vaccine and autologous T cell